B Cell Lymphoma
Conference Coverage
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
From the Journals
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
From the Journals
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
From the Journals
Intravenous CNS chemo looks best for testicular DLBCL
Intrathecal chemotherapy did not offer a benefit, according to findings from the retrospective analysis of patients with testicular diffuse large...
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
Acalabrutinib extends PFS in advanced CLL
AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...
Conference Coverage
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
From the Journals
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
Conference Coverage
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...